Key points are not available for this paper at this time.
The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.
Enlimomab Acute Stroke Trial Investigators (Tue,) studied this question.